Abstract

Pulmonary hypertension (PH) is a progressive vascular disease characterized by right ventricular failure and high mortality rates. Monotherapy in treatment strategies has shown limited efficacy, leading to an increasing emphasis on combination therapy approaches. Combination therapy involves the concurrent use of agents targeting different pathways, such as endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, and prostacyclin analogs. This approach can result in significant reductions in vascular resistance, improvements in quality of life, and a slowing of disease progression. Recent clinical studies have demonstrated that combination therapy is superior to monotherapy in both hemodynamic parameters and long-term patient outcomes. This review aims to explore the efficacy, safety, and potential future research areas of combination strategies in the treatment of PH.